Johnson & Johnson’s (J&J) Biosense Webster has acquired US-based medical device firm Coherex Medical, for undisclosed sum.

Coherex Medical produces WaveCrest left atrial appendage (LAA) occlusion system, which received CE mark approval in September 2013.

The company has developed the device to permanently occlude the LAA in high-risk atrial fibrillation (Afib) patients, allowing to reduce the incidence of stroke caused by the migration of blood clots formed in the LAA.

Coherex WaveCrest is currently not available for investigational use or commercial distribution in the US.

Johnson & Johnson company group chairman Shlomi Nachman said: "The addition of the Coherex WaveCrest system complements our comprehensive portfolio of therapeutic solutions for patients suffering from atrial fibrillation who not only suffer from reduced quality of life but also face a significantly greater risk of a stroke."

Coherex Medical president and CEO Alex Martin said: "The Coherex WaveCrest system offers substantial benefits for patients with atrial fibrillation who are at high risk for stroke, particularly for those who are contraindicated to anticoagulants and would therefore, be unprotected from the risk of cardio embolism."

Biosense develops novel technologies to diagnose and treat heart rhythm disorders.